AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17054108 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC-HD (fluorouracil 750 mg/m(2) on Days 1 to 4, epirubicin 35 mg/m(2) on Days 2 to 4, cyclophosphamide 400 mg/m(2) on Days 2 to 4 for 4 cycles every 21 days) with lenograstim
Number of subjects: 120
Study 17054108 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 75 (fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), cyclophosphamide 500 mg/m(2) on Day 1 every 21 days for 4 cycles)
Number of subjects: 120
Study 17054108 — intervention group
Group type: COMPARATOR
Intervention: FEC-HD (without lenograstim)
Number of subjects: 120
Study 14609434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravelle
Number of subjects: 238
Study 14609434 — intervention group
Group type: COMPARATOR
Intervention: Follistim
Number of subjects: 238
Study 10998604 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW threat condition (40 cm)
Number of subjects: 62
Study 10998604 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDIUM threat condition (100 cm)
Number of subjects: 62
Study 10998604 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH threat condition (160 cm)
Number of subjects: 62
Study 10998604 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending order (HIGH threat first)
Number of subjects: 62
Study 10998604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending order (LOW threat first)
Number of subjects: 62
Study 10998604 — intervention group
Group type: EXPERIMENTAL
Intervention: First trial at LOW threat condition
Number of subjects: 62
Study 8694298 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.25 or 2.5 mg/kg
Number of subjects: 0
Study 8694298 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone 0.5 or 1 mg/kg
Number of subjects: 0
Study 8694298 — intervention group
Group type: COMPARATOR
Intervention: Lipid emulsion only
Number of subjects: 0
Study 1461627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose megestrol acetate (480 mg/day)
Number of subjects: 91
Study 1461627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (960 mg/day)
Number of subjects: 91
Study 1461627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 6322207 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (10 to 40 mg per day) with hydrochlorothiazide (50 mg per day) and alpha-methyldopa (250 to 1000 mg per day if necessary)
Number of subjects: 24
Study 6322207 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg per day) with propranolol (80 to 240 mg per day) and hydralazine (100 to 200 mg per day if necessary)
Number of subjects: 24
Study 30855708 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10 sessions, one daily)
Number of subjects: 82
Study 30855708 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS treatment
Number of subjects: 82
Study 30855708 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 82
Study 29463150 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg prasugrel
Number of subjects: 3747
Study 29463150 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel
Number of subjects: 3747
Study 26903430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rap music use
Number of subjects: 443
Study 26903430 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived peer sexual behavior (mediator)
Number of subjects: 443
Study 24583820 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg i.v. dexamethasone
Number of subjects: 60
Study 24583820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22788925 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhanced enteral nutrition (EN + glutamine [Gln])
Number of subjects: 78
Study 22788925 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard enteral nutrition (EN)
Number of subjects: 78
Study 22788925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 20961269 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 132
Study 20961269 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (1000 mg/day)
Number of subjects: 132
Study 17714677 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected intercourse (no barrier contraception)
Number of subjects: 0
Study 17714677 — intervention group
Group type: EXPERIMENTAL
Intervention: Male partner's unwillingness to use condoms
Number of subjects: 0
Study 17714677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low condom use self‐efficacy score (for women < 20 years old)
Number of subjects: 0
Study 15653007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined HRT (1 mg 17beta-estradiol plus 0.5 mg norethisterone acetate)
Number of subjects: 100
Study 15653007 — intervention group
Group type: COMPARATOR
Intervention: Sequential combined HRT (0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days)
Number of subjects: 100
Study 12040969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac effervescent tablet (DIC-BT) 150 mg/d for 7 days
Number of subjects: 100
Study 12040969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac enteric coated dragees (DIC-mrD) 150 mg/d for 7 days
Number of subjects: 100
Study 12040969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible tablets (DIC-DispT) 150 mg/d for 7 days
Number of subjects: 100
Study 12040969 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 1500 mg/d for 7 days (positive control)
Number of subjects: 100
Study 9620500 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (CE) 100 mg i.v. (20 mL) at the beginning of the procedure and a second dose of CE (100 mg i.v.) just after reperfusion of the new graft.
Number of subjects: 0
Study 9620500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL of isotonic sodium chloride solution) at the beginning of the procedure and a second dose of placebo (20 mL of isotonic sodium chloride solution) just after reperfusion of the new graft.
Number of subjects: 0
Study 10150762 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous bypass
Number of subjects: 8
Study 2360542 — intervention group
Group type: EXPERIMENTAL
Intervention: New milk product (860 mL)
Number of subjects: 0
Study 2360542 — intervention group
Group type: COMPARATOR
Intervention: Normal milk (1000 mL)
Number of subjects: 0
Study 466138 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 53
Study 466138 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 53
Study 30829563 — intervention group
Group type: COMPARATOR
Intervention: Family history of stroke (overall)
Number of subjects: 3878
Study 30829563 — intervention group
Group type: COMPARATOR
Intervention: Maternal stroke history
Number of subjects: 3878
Study 30829563 — intervention group
Group type: COMPARATOR
Intervention: Stroke onset age <55 years with family history
Number of subjects: 3878
Study 30829563 — intervention group
Group type: COMPARATOR
Intervention: Thrombotic stroke in patients with family history
Number of subjects: 3878
Study 27919204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 87
Study 27919204 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 87
Study 25850535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-frequency bioimpedance electrical analysis (BIS)
Number of subjects: 964
Study 25850535 — intervention group
Group type: COMPARATOR
Intervention: Perometer arm measurement
Number of subjects: 964
Study 25850535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (BIS and Perometer)
Number of subjects: 964
Study 25850535 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold for early intervention
Number of subjects: 964
Study 25850535 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms reported by patients with no lymphoedema
Number of subjects: 964
Study 23426275 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Care Group (ACG) - received usual care plus regular information and encouragement on cardiovascular risk factors by email or letter.
Number of subjects: 55
Study 23426275 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - received regular care.
Number of subjects: 55
Study 20605698 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron, thiamine, riboflavin, folic acid, niacinamide, zinc, and calcium (Group III)
Number of subjects: 226
Study 20605698 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A plus iron (Group II)
Number of subjects: 226
Study 20605698 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A (Group I)
Number of subjects: 226
Study 19438468 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratrochlear and supraorbital nerve block
Number of subjects: 34
Study 19438468 — intervention group
Group type: COMPARATOR
Intervention: Cold air analgesia
Number of subjects: 34
Study 17265458 — intervention group
Group type: EXPERIMENTAL
Intervention: T2000 (400 mg)
Number of subjects: 34
Study 17265458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17265458 — intervention group
Group type: EXPERIMENTAL
Intervention: T2000 (300 mg)
Number of subjects: 34
Study 17265458 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of T2000 (800 mg daily)
Number of subjects: 34
Study 15141410 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber diet
Number of subjects: 8
Study 15141410 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble fiber diet
Number of subjects: 8
Study 15141410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric feeding
Number of subjects: 8
Study 15141410 — intervention group
Group type: COMPARATOR
Intervention: Control (no fiber added)
Number of subjects: 8
Study 12666946 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazole dental gel applied subgingivally on days 0 and 7 as an adjunct to scaling and root planing (SRP)
Number of subjects: 18
Study 12666946 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 18
Study 9210122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear amplification
Number of subjects: 110
Study 9210122 — intervention group
Group type: EXPERIMENTAL
Intervention: BILL processing
Number of subjects: 110
Study 7659916 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine solution using 50% dimethylsulfoxide as a vehicle
Number of subjects: 8
Study 7659916 — intervention group
Group type: COMPARATOR
Intervention: Similar solution without cyclosporine
Number of subjects: 8
Study 2891032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 130
Study 2891032 — intervention group
Group type: COMPARATOR
Intervention: Antacids or H2 blockers
Number of subjects: 130
Study 29510649 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 mg)
Number of subjects: 0
Study 29510649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (100 mg)
Number of subjects: 0
Study 29510649 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 27824633 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (6 to 18 g/day)
Number of subjects: 38
Study 27824633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25749502 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/d for 5 days and then every third day (12 total doses) + darbopoietin α 40 mcg/wk for 4 weeks (GDP group)
Number of subjects: 55
Study 25749502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 55
Study 25749502 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) + darbopoietin α (GDP group)
Number of subjects: 55
Study 23438706 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 115
Study 23438706 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 115
Study 20403998 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (36% of participants, n = 730)
Number of subjects: 2035
Study 20403998 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use for >3 years
Number of subjects: 2035
Study 20403998 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib treatment (200 mg and 400 mg)
Number of subjects: 2035
Study 20403998 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 2035
Study 18280869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program for 16 weeks
Number of subjects: 46
Study 15718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program
Number of subjects: 200
Study 15718182 — intervention group
Group type: COMPARATOR
Intervention: Standard care (outpatient heart failure clinic)
Number of subjects: 200
Study 12456380 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous montelukast (7 or 14 mg)
Number of subjects: 201
Study 12456380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 10615075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of floxuridine plus systemic fluorouracil (with or without leucovorin)
Number of subjects: 156
Study 10615075 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy alone (monotherapy)
Number of subjects: 156
Study 8941833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibers
Number of subjects: 25
Study 8941833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibers with scaling and root planing
Number of subjects: 25
Study 1768058 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasio only treatment
Number of subjects: 63
Study 1768058 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose gestagen therapy recommended for patients with CGH and high PgR concentration
Number of subjects: 63
Study 7009309 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side portacaval shunt
Number of subjects: 89
Study 7009309 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 89
Study 30368658 — intervention group
Group type: COMPARATOR
Intervention: Tylerdipine 5-30 mg (SAD study)
Number of subjects: 88
Study 30368658 — intervention group
Group type: COMPARATOR
Intervention: Tylerdipine 10 or 20 mg (MAD study)
Number of subjects: 88
Study 30368658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAD study)
Number of subjects: 88
Study 30368658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MAD study)
Number of subjects: 88
Study 28664722 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug consumption among adolescents
Number of subjects: 17331
Study 28664722 — intervention group
Group type: EXPERIMENTAL
Intervention: Designer drug consumption
Number of subjects: 17331
Study 28664722 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about designer drugs
Number of subjects: 17331
Study 26407095 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil (2 g/day)
Number of subjects: 37
Study 26407095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23371457 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitongning Capsule
Number of subjects: 120
Study 23371457 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 120
Study 21338506 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure intervention consisting of two 90 minute group sessions provided by a qualified counsellor and a co-facilitator.
Number of subjects: 0
Study 21338506 — intervention group
Group type: COMPARATOR
Intervention: Control condition receiving standard substance use education sessions as per the Dutch national curriculum.
Number of subjects: 0
Study 18978640 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 53
Study 18978640 — intervention group
Group type: COMPARATOR
Intervention: Symptom diary control
Number of subjects: 53
Study 17679661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention provided by nurse home visitors (environmental allergen and tobacco smoke reduction, illness management) for 12 months
Number of subjects: 149
Study 17679661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 149
Study 15042388 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP therapy with 5000 IU heparin pretreatment (H group)
Number of subjects: 18
Study 15042388 — intervention group
Group type: COMPARATOR
Intervention: Conventional EECP therapy (C group)
Number of subjects: 18
Study 15042388 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP therapy with heparin pretreatment (H group)
Number of subjects: 18
Study 11890513 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative-dynamic image synthesis
Number of subjects: 69
Study 11890513 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 69
Study 11890513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10923530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 105
Study 10923530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 105
Study 10923530 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 105
Study 8166475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platinum or carboplatin containing regimens
Number of subjects: 1527
Study 8166475 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction regimens (Etoposide (VP-16) and Teniposide (VM-26))
Number of subjects: 1527
Study 8166475 — intervention group
Group type: COMPARATOR
Intervention: Control arm (alternating regimen)
Number of subjects: 1527
Study 8166475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocols
Number of subjects: 1527
Study 2844044 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber band ligation (RBL) + unprocessed bran (twice-daily intake for 18 months)
Number of subjects: 92
Study 2844044 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation (RBL) alone
Number of subjects: 92
Study 29573212 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 3456
Study 29573212 — intervention group
Group type: EXPERIMENTAL
Intervention: General medication use
Number of subjects: 3456
Study 29573212 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use by age
Number of subjects: 3456
Study 29573212 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol use by age
Number of subjects: 3456
Study 29573212 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 3456
Study 28707771 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone daily from 18 to 34 weeks gestation
Number of subjects: 57
Study 28707771 — intervention group
Group type: COMPARATOR
Intervention: Placebo ovule daily from 18 to 34 weeks gestation
Number of subjects: 57
Study 28707771 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone
Number of subjects: 57
Study 28707771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 26589142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-warmed SLIPA (37 °C)
Number of subjects: 90
Study 26589142 — intervention group
Group type: COMPARATOR
Intervention: Room temperature SLIPA
Number of subjects: 90
Study 24408336 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine tablet
Number of subjects: 58
Study 24408336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 21176950 — intervention group
Group type: EXPERIMENTAL
Intervention: 440 mg albendazole and 40 mg/kg praziquantel
Number of subjects: 2507
Study 21176950 — intervention group
Group type: EXPERIMENTAL
Intervention: 440 mg albendazole
Number of subjects: 2507
Study 21176950 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kg praziquantel
Number of subjects: 2507
Study 17909085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon
Number of subjects: 282
Study 17909085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 17165280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene modifier drugs
Number of subjects: 676
Study 17165280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene modifier drugs in combination with systemic corticosteroids
Number of subjects: 676
Study 14763200 — intervention group
Group type: EXPERIMENTAL
Intervention: One insertion of quinacrine pellets
Number of subjects: 100
Study 14763200 — intervention group
Group type: COMPARATOR
Intervention: Two insertions of quinacrine pellets
Number of subjects: 100
Study 11068974 — intervention group
Group type: COMPARATOR
Intervention: TNS + placebo
Number of subjects: 224
Study 11068974 — intervention group
Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (20 mg)
Number of subjects: 224
Study 11068974 — intervention group
Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (40 mg)
Number of subjects: 224
Study 11068974 — intervention group
Group type: COMPARATOR
Intervention: TNS + placebo (compliant participants)
Number of subjects: 224
Study 11068974 — intervention group
Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (20 mg) (compliant participants)
Number of subjects: 224
Study 11068974 — intervention group
Group type: EXPERIMENTAL
Intervention: TNS + paroxetine (40 mg) (compliant participants)
Number of subjects: 224
Study 8616547 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly follow-up of pulmonary rehabilitation after home rehabilitation (Group A)
Number of subjects: 36
Study 8616547 — intervention group
Group type: EXPERIMENTAL
Intervention: Once monthly follow-up of pulmonary rehabilitation after home rehabilitation (Group B)
Number of subjects: 36
Study 8616547 — intervention group
Group type: COMPARATOR
Intervention: No rehabilitation at all (Group C)
Number of subjects: 36
Study 1424417 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 92
Study 1424417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac by titration
Number of subjects: 92
Study 1424417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac by bolus injection
Number of subjects: 92
Study 3916836 — intervention group
Group type: EXPERIMENTAL
Intervention: liposteroid (2.5 mg of dexamethasone)
Number of subjects: 138